Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Carcinoma, Hepatocellular 19Neoplasm Metastasis 13Melanoma 12Nasopharyngeal Carcinoma 10Carcinoma, Non-Small-Cell Lung 10Stomach Neoplasms 8Rectal Neoplasms 8Pancreatic Neoplasms 8Colorectal Neoplasms 8Squamous Cell Carcinoma of Head and Neck 6Neoplasms 6Locally Advanced Rectal Cancer 6Carcinoma, Renal Cell 6Uterine Cervical Neoplasms 4Recurrence 4Lymphoma, Extranodal NK-T-Cell 4Triple Negative Breast Neoplasms 3Sarcoma 3Nasopharyngeal Neoplasms 3Glioblastoma 3Esophageal Squamous Cell Carcinoma 3Esophageal Neoplasms 3Cholangiocarcinoma 3Thyroid Neoplasms 2Solid Tumor 2Prostatic Neoplasms 2Lymphoma 2Lung Neoplasms 2Kidney Neoplasms 2Gastrointestinal Stromal Tumors 2

Interventions

Iodine-131 5dabrafenib 4Vemurafenib 4Magnetic Resonance Spectroscopy 4trametinib 3lenvatinib 3Transurethral Resection of Prostate 3Thyrotropin Alfa 3Thyroidectomy 3selpercatinib 2cobimetinib 2X-Rays 2Thyroid (USP) 2Surgical Procedures, Operative 2Sunitinib 2Specimen Handling 2Radiofrequency Ablation 2Interviews as Topic 2vandetanib 1tremelimumab 1spartalizumab 1pembrolizumab 1pazopanib 1durvalumab 1delta 24-sterol reductase 1copanlisib 1cabozantinib 1Whole Body Imaging 1Thyrotropin 1Thalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Thyroid Cancer, Papillary × spartalizumab × Clear all
NCT04544111 2025-10-07

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
19 enrolled
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenoma, Oxyphilic, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡